stoxline Quote Chart Rank Option Currency Glossary
  
Mesa Laboratories, Inc. (MLAB)
127.93  -5.48 (-4.11%)    11-20 16:00
Open: 131.33
High: 133.93
Volume: 76,014
  
Pre. Close: 133.41
Low: 126.73
Market Cap: 719(M)
Technical analysis
2026-11-20 4:46:13 PM
Short term     
Mid term     
Targets 6-month :  155.82 1-year :  166.94
Resists First :  133.41 Second :  142.92
Pivot price 131.14
Supports First :  118.01 Second :  98.18
MAs MA(5) :  133.56 MA(20) :  130.92
MA(100) :  119.58 MA(250) :  102.28
MACD MACD :  1.5 Signal :  1.5
%K %D K(14,3) :  60.3 D(3) :  66.6
RSI RSI(14): 46.7
52-week High :  144.35 Low :  69.73
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MLAB ] has closed above bottom band by 36.8%. Bollinger Bands are 38.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 133.99 - 134.89 134.89 - 135.63
Low: 125.06 - 125.91 125.91 - 126.61
Close: 126.68 - 128.07 128.07 - 129.21
Company Description

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Headline News

Thu, 12 Nov 2026
Mesa Laboratories (MLAB) counsel’s stock units start vesting at 34% on November 10, 2027. - Stock Titan

Mon, 09 Nov 2026
Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript - The Motley Fool

Mon, 09 Nov 2026
Mesa Labs: Fiscal Q2 Earnings Snapshot - KVUE

Mon, 09 Nov 2026
Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance - Yahoo Finance

Mon, 09 Nov 2026
What Mesa Laboratories (MLAB) Said on Its Q2 Earnings Call - TradingView

Mon, 09 Nov 2026
Mesa Laboratories, Inc. Q2 2027 Earnings Call Summary - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Specialties
Shares Out 6 (M)
Shares Float 5 (M)
Held by Insiders 5.5 (%)
Held by Institutions 101.2 (%)
Shares Short 391 (K)
Shares Short P.Month 404 (K)
Stock Financials
EPS 0.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 33.72
Profit Margin 1.9 %
Operating Margin 11.6 %
Return on Assets (ttm) 3.2 %
Return on Equity (ttm) 2.6 %
Qtrly Rev. Growth 1 %
Gross Profit (p.s.) 28.63
Sales Per Share 44.59
EBITDA (p.s.) 8.11
Qtrly Earnings Growth -42.5 %
Operating Cash Flow 56 (M)
Levered Free Cash Flow 53 (M)
Stock Valuations
PE Ratio 150.5
PEG Ratio 0
Price to Book value 3.79
Price to Sales 2.86
Price to Cash Flow 12.86
Stock Dividends
Dividend 0.15
Forward Dividend 0
Dividend Yield 0.1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android